Article Text

PDF
Expression of calcitonin receptor-like receptor in human vascular tumours
  1. S Hagner1,
  2. U Stahl2,
  3. T Grimm3,
  4. M Stürzl4,
  5. R E Lang1
  1. 1Institute of Physiology, Philipps-University Marburg, Marburg, Germany
  2. 2Institute of Pathology and Zytology, Wetzlar, Germany
  3. 3Institute of Molecular Virology, Neuherberg, Germany
  4. 4Molecular and Experimental Surgery, Department of Surgery, University of Erlangen-Nürnberg, Nürnberg, Germany
  1. Correspondence to:
 S Hagner
 Institut für Normale und Pathologische Physiologie, Philipps-Universität Marburg, Deutschhausstr 2, D-35037 Marburg, Germany; hagnerbe{at}staff.uni-marburg.de

Abstract

Background: Vascular tumours such as Kaposi’s sarcoma and capillary haemangioma are characterised by abnormal vascularisation and proliferation of endothelial cells or neoplastic cells. Adrenomedullin, a potent vasodilative peptide, and its receptor, calcitonin receptor-like receptor (CRLR), play an important part in angiogenesis.

Aim: To establish whether this system also plays a part in vascular diseases, showing abnormal proliferation such as vascular tumours.

Methods: CRLR expression was investigated in several specimens of Kaposi’s sarcoma and other vascular tumours, using immunohistochemical analysis with a previously described CRLR-specific polyclonal antibody and reverse transcriptase-polymerase chain reaction.

Results: Intense and specific CRLR-immunoreactive staining of neoplastic cells was observed in all specimens, which was of greater intensity than similar staining of adjacent normal endothelium.

Conclusions: CRLR is expressed in vascular tumours and, with adrenomedullin, may have a role in neoplastic vascular growth.

  • ADM, adrenomedullin
  • CRLR, calcitonin receptor-like receptor
  • CRLR-LI, calcitonin receptor-like receptor-like immunoreactivity
  • PCR, polymerase chain reaction
  • RAMP, receptor activity-modifying protein
  • VEGF, vascular endothelial-derived growth factor

Statistics from Altmetric.com

Footnotes

  • Competing interests: None declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.